Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT04820322 |
Other study ID # |
GIL-1852 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
August 24, 2018 |
Est. completion date |
October 19, 2018 |
Study information
Verified date |
March 2021 |
Source |
MGP Ingredients, Inc. |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Fibersym® is a RS4-type resistant modified wheat starch in which over 85% of the total starch
is resistant starch as measured by AOAC method 991.43. It is meant to be consumed on a
regular basis and doses up to 33g/day can be tolerated. The effect of a Fibersym-containing
meal on postprandial glucose and insulin levels when compared to a control meal, where both
meals contain the same amount of available carbohydrate, is not known. This study therefore
investigated the acute effect of a Fibersym cookie and a control cookie matched for available
carbohydrate after a 3-day habituation period.
Description:
The study used a double-blind, randomized, cross-over design.
Visit 1: Participants willing to be considered were invited to come to the research centre to
have the study procedures explained to them and be given a copy of the consent form which
they may either sign then, take away to sign at a later date, or decline to participate.
Participants were encouraged to ask any questions they may have and not to sign the consent
form until all of their questions have been answered to their satisfaction. Those who
consented to participate came to the research centre for a pre-selection visit when subject
eligibility will be determined. A number of parameters were assessed including blood
pressure, weight, height, BMI, and brief medical history.
Visit 2-3: Eligible subjects were randomized using an online randomization calculator.
Eligible subjects were studied on 2 separate days over a period of 6 weeks or less. Prior to
each test meal, they were provided with enough cookies to consume 3 times/day over 3 days and
instructed to start consuming the cookies 3 days before their visit. They were also provided
with a calorie appropriate, standard frozen dinner to be consumed on the evening before their
test meal. The interval between successive tests was no less than 6 days and no more than 4
weeks. On each test day, participants came to GI Labs in the morning after a 10-12 h
overnight fast (except for water). Participants were asked to maintain stable dietary and
activity habits throughout their participation and to refrain from drinking alcohol and from
unusual levels of food intake or physical activity for 24 h before each test. Before the
start of the test meal, subjects were asked whether they consumed the provided cookies over
the last 3 days as instructed and the standard dinner the evening before. Subjects were asked
to complete a 3- day record of supplement consumption and whether they consumed the standard
evening meal, in addition to a 3-day symptom diary before each test visit. If any subject was
not feeling well or had not complied with the preceding experimental conditions, the test was
not carried out and was rescheduled for another day. On each test day, two fasting
fingerprick blood samples were collected at -5 min and 0 min. Each sample consisted of 2
vials, one for glucose analysis and one for insulin analysis (4-8 drops of blood each).
Questionnaires to record satiety and GI symptoms were administered. Participants were then
given the test food together with 250 ml of water and instructed to consume them over 15
minutes. Additional blood samples were collected 15, 30, 45, 60, 90 and 120 min after the
start of the test meal. Satiety questionnaires were administered at the same time intervals.
GI symptom questionnaires were filled out at 2 h in addition to fasting.
Test Foods:
The sugar snap cookie formula (Control) was obtained from the American Institute of Baking
(AIB) International (Manhattan, KS). Fibersym RW (Appendix 1) was added as an extra portion
to the Control Cookie recipe, amounts were adjusted so that both the control and Fibersym
cookie portions contained the same amount of available carbohydrate (ingredients are listed
in appendix 1). Both cookies were baked at the facilities of AIB. The macronutrient
composition of baked cookies was determined by an independent laboratory and the final
weights of the cookies fed were adjusted accordingly.
For the test breakfasts during the postprandial visit, the subject consumed approximately 3
cookies containing 40 g available carbohydrates, the weight of Control Cookies per meal was
78.1g whereas the weight of Fibersym Cookies per meal was 97.8 g (delivering 21 g of fiber
from Fibersym and 2.1g from the flour) (Table 1). Both test meals were consumed with 250 ml
of water.
During the 3-day pre-feeding period, subjects consumed 108.9g cookies (approx. 3.5) of
Control Cookies per day and 136.2 g of Fibersym Cookies (approx. 4) per day (delivering 29 g
fiber from Fibersym/day). The cookies were consumed during the 3 meals (breakfast, lunch and
dinner). Both the control and Fibersym cookies contributed 50g available carbohydrate per
day. The product was re-packaged by a GI Labs staff member not involved in the clinical
trial. Product label displayed the subject number, subject initials, product ID, ingredients
statement, GIL repacked date, expiration date, researcher name and telephone number,
investigational use statement, and allergy warnings (if needed). Study Product Intake Logs
were completed upon dispensation of study product to each subject. After the data had been
entered, checked for errors and the database locked, the code was broken, #149 corresponded
to the control cookie while 394 corresponded to the Fibersym cookie.
All subjects were asked to consume a standard evening meal provided by GI Labs and consisted
of a frozen dinner.